RP Scherer Corp has signed two agreements with major pharmaceuticalcompanies regarding Zydis technology, the group's fast-dissolving drug delivery system.
The deal with Japanese drugmaker Sankyo relates to formulations of an unnamed leading compound from Sankyo's product portfolio in Zydis dosage form. Under the terms of the agreement, Sankyo will pay Scherer undisclosed sums to develop the product and, in exchange, Sankyo will obtain exclusive worldwide marketing rights.
Meantime, the group's Scherer DDS unit and Elan Corp's Elan Pharma International subsidiary have agreed to extend the latter's Zydis selegiline licensing accord to include Europe, where it is currently under review for marketing approval. Elan currently holds marketing rights for the oral treatment for Parkinson's disease in the USA, Canada and other markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze